EcoDrugPlus

Mitogen-Activated Protein Kinase 11-Like

Ensembl ID : ENSXMAG00000010248
Gene Symbol: LOC102223674
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a

Ensembl ID : ENSXMAG00000024923
Gene Symbol: LOC102231047
3 Cross references
224 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a-Like

Ensembl ID : ENSXMAG00000010317
Gene Symbol: LOC102218102
3 Cross references
206 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSXMAG00000009503
Gene Symbol: MAPK8
3 Cross references
224 Possible Orthologues:

Mitogen-Activated Protein Kinase 8-Like

Ensembl ID : ENSXMAG00000013557
Gene Symbol: LOC102234094
4 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSXMAG00000008807
Gene Symbol: MAPK9
3 Cross references
210 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSXMAG00000003499
Gene Symbol: MAP2K1
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSXMAG00000021375
Gene Symbol: MAP2K2
3 Cross references
212 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSXMAG00000018686
Gene Symbol: MAP3K10
3 Cross references
182 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSXMAG00000011458
Gene Symbol: MAP3K11
3 Cross references
178 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSXMAG00000017771
Gene Symbol: MAP3K12
4 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12-Like

Ensembl ID : ENSXMAG00000016777
Gene Symbol: LOC102221308
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).